Spruce Street Capital »

Sab Biotherapeutics shares owned by Spruce Street Capital

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Spruce Street Capital from 13F filings

Historical chart of Spruce Street Capital investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Spruce Street Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $8.6M 2.2M 3.90

More positions owned by Spruce Street Capital

Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Relay Therapeutics (RLAY)
Lb Pharmaceuticals Com Shs (LBRX)
Relmada Therapeutics (RLMD)
Alto Neuroscience Com Shs (ANRO)
Dianthus Therapeutics (DNTH)
Alkermes SHS (ALKS)
Savara (SVRA)
Vaxcyte (PCVX)
Enliven Therapeutics (ELVN)
Enanta Pharmaceuticals (ENTA)
Perspective Therapeutics Com New (CATX)
Inflarx Nv (IFRX)
Surrozen Com New (SRZN)
Alumis (ALMS)

View all positions for Spruce Street Capital

Top funds holding Sab Biotherapeutics

Vivo Capital
Caligan Partners
Perceptive Advisors
Commodore Capital
RA Capital Management
Balyasny Asset Management
Adage Capital Partners GP
Millennium Management
Vanguard Capital Management
Woodline Partners
Spruce Street Capital
Sessa Capital IM
Affinity Asset Advisors
Boothbay Fund Management
Ameriprise Financial

View all funds holding Sab Biotherapeutics